Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2019 06:00 ET | Source: Invivoscribe, Inc.

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

SAN DIEGO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- For twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and...
November 29, 2018 06:00 ET | Source: Invivoscribe, Inc.

US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US

SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and the Astellas drug, XOSPATA (gilteritinib fumarate),...
November 19, 2018 08:00 ET | Source: Invivoscribe, Inc.

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan

SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...
September 27, 2018 06:00 ET | Source: Invivoscribe, Inc.

Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)

SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Invivoscribe® Inc., a global company providing biomarker and clonality test solutions for the fields of oncology and personalized molecular medicine®...
June 19, 2013 08:36 ET | Source: Invivoscribe Technologies, Inc.

Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling

SAN DIEGO, CA--(Marketwired - Jun 19, 2013) - In Association of Molecular Pathology v. Myriad, the U.S. Supreme Court struck down BRCA1 and BRCA2 gene patent claims. It is important for the...
February 15, 2011 16:00 ET | Source: Invivoscribe Technologies, Inc.

Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic Test

SAN DIEGO, CA--(Marketwire - February 15, 2011) - Invivoscribe™ Technologies, Inc., a world leader in personalized molecular medicine, announced today that they have entered into a...